Search
Selected Filter
Displaying 1–10 of 184 research results
-
AGTC Reports Positive Six-Month Results for XLRP Phase 1/2 Gene Therapy Trial
The company is planning a Phase 3, pivotal trial for end of 2020
-
First Human Study in US for Induced Pluripotent Stem Cells to be Launched for Advanced Dry AMD
Currently there are no treatments for Advanced Dry AMD, also known as GA, which can lead to significant central vision loss
-
First Patient Receives ProQR’s AON Therapy in Clinical Trial for RP Caused by RHO-P23H Mutation
The trial becomes ProQR’s third human study for inherited retinal disease therapies
-
Families and Scientists Meet to Discuss Therapy Development for People with RDH12 Mutations
Proof-of-concept for RDH12 gene therapy demonstrated in mouse model
-
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Phase 1/2a human study will evaluate neural progenitors for preserving vision
-
AGTC Announces Development of Stargardt Disease Gene Therapy
Dual-vector delivery system designed to deliver the large ABCA4 gene
-
Iveric Bio’s Therapy Slows Retinal Degeneration in Phase 2b Trial for Dry AMD
Zimura inhibits a complement protein known as C5, a component of the immune system that, when overactive, can cause retinal degeneration.
-
ReNeuron Reports Interim Results for Eight Patients with RP in Phase 2a Trial for Stem Cell Therapy
The Foundation funded earlier lab studies that made the clinical trial possible.
-
FDA Approves New Wet AMD Treatment that can be Administered Every Three Months
Beovu from Novartis reduces treatment burden for wet AMD patients
-
AGTC Reports Promising Interim Results for XLRP and Achromatopsia Gene Therapy Trials
AGTC used Foundation’s My Retina Tracker registry to recruit patients for trials
